Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1150 Neoplasms 914 Carcinoma, Non-Small-Cell Lung 763 Prostatic Neoplasms 678 Colorectal Neoplasms 517 Lung Neoplasms 498 Neoplasm Metastasis 380 Multiple Myeloma 366 Leukemia, Myeloid, Acute 348 Ovarian Neoplasms 327 Melanoma 311 Pancreatic Neoplasms 291 Squamous Cell Carcinoma of Head and Neck 259 Recurrence 252 Brain Neoplasms 239 Carcinoma, Hepatocellular 238 Stomach Neoplasms 224 Lymphoma 210 Glioblastoma 209 Uterine Cervical Neoplasms 207 Endometrial Neoplasms 203 Head and Neck Neoplasms 202 Triple Negative Breast Neoplasms 198 Urinary Bladder Neoplasms 197 Precursor Cell Lymphoblastic Leukemia-Lymphoma 196 Carcinoma, Renal Cell 182 Leukemia, Lymphocytic, Chronic, B-Cell 171 Hematologic Neoplasms 169 Glioma 167 Lymphoma, Non-Hodgkin 166

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡